Form 4: ImmunityBio Director Soon-Shiong Exercises Stock Options, Maintains Significant Ownership

Patrick Soon-Shiong, a director and significant shareholder of ImmunityBio, exercised restricted stock units and reported changes in beneficial ownership, maintaining a substantial stake in the company through various entities.

Summary

• Patrick Soon-Shiong, a director, 10% owner, and officer of ImmunityBio, exercised 114,329 restricted stock units (RSUs) on February 22, 2025.
• The exercise price for the RSUs was $0, resulting in the acquisition of 114,329 shares of ImmunityBio common stock.
• Simultaneously, 42,071 shares were disposed of at a price of $3.42 per share.
• Following these transactions, Soon-Shiong directly owns 29,546,190 shares of ImmunityBio common stock.
• Soon-Shiong also indirectly owns a significant number of shares through various entities, including Nant Capital, Cambridge Equities, NantBio, California Capital Equity, the Chan Soon-Shiong Family Foundation, NantWorks, NantMobile, and NantCancerStemCell.
• The total indirect ownership amounts to hundreds of millions of shares.
• The vesting commencement date for the RSU award was February 22, 2024, with vesting occurring in annual installments.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document primarily reports transactions. The exercise of options is generally positive, but the disposal of shares introduces a slightly negative element. The large existing ownership stake suggests continued commitment.

Positives

• The exercise of RSUs indicates confidence in the company's future prospects by a key insider.
• Soon-Shiong maintains a significant ownership stake, aligning his interests with those of other shareholders.

Negatives

• The disposal of 42,071 shares, although a small portion of his holdings, could be interpreted negatively by some investors.

Risks

• The complex ownership structure involving multiple entities could create opacity and potential conflicts of interest.
• Future transactions by Soon-Shiong or related entities could impact the stock price.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the RSUs suggests continued service and involvement of Soon-Shiong with ImmunityBio.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to the market regarding their transactions.

Comparison to Industry Standards

• Tracking insider transactions is a common practice in financial analysis to gauge management's sentiment and potential future performance.
• Comparing Soon-Shiong's ownership stake and transaction history with those of insiders at comparable biotech companies (e.g., Amgen, Gilead Sciences) can provide valuable context.
• The complexity of the ownership structure through multiple entities is not uncommon among high-net-worth individuals and investment firms.

Stakeholder Impact

• The transactions could influence investor sentiment and potentially the stock price.
• The continued involvement of Soon-Shiong is likely viewed positively by employees and other stakeholders.

Key Dates